This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Bebetter Med Inc.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Yunwo Weng
Introduction
Yunwo Weng is a notable inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating cancer. His work focuses on innovative solutions that target specific mutations in cancer cells.
Latest Patents
Yunwo Weng holds a patent for a compound known as 2,4-bis(nitrogen-containing group)-substituted pyrimidine. This compound is represented by a general formula (I) and includes a preparation method and its use in anti-tumor drug development. The compound selectively suppresses the activity of mutant epidermal growth factor receptors (EGFR), including the T790M mutation, which is associated with non-small cell lung cancer (NSCLC). This innovation has the potential to improve treatment options for patients with specific EGFR mutations.
Career Highlights
Weng is currently employed at Bebetter Med Inc., where he continues to advance his research in pharmaceutical innovations. His work has garnered attention for its potential impact on cancer treatment, particularly in targeting resistant forms of the disease.
Collaborations
Yunwo Weng collaborates with talented colleagues, including Xiong Cai and Bin Liu. Their combined expertise contributes to the innovative environment at Bebetter Med Inc., fostering advancements in medical research.
Conclusion
Yunwo Weng's contributions to the field of pharmaceuticals, particularly through his patented compound, highlight his role as an influential inventor. His work has the potential to significantly impact cancer treatment, showcasing the importance of innovation in medicine.